{"id":44926,"date":"2022-06-09T23:01:55","date_gmt":"2022-06-09T21:01:55","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/"},"modified":"2022-06-09T23:01:55","modified_gmt":"2022-06-09T21:01:55","slug":"pulse-biosciences-inc-announces-the-closing-of-its-rights-offering","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/","title":{"rendered":"Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering"},"content":{"rendered":"
\n

HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (the \u201cCompany\u201d or \u201cPulse Biosciences\u201d), a novel bioelectric medicine company commercializing the CellFX\u00ae System powered by Nano-Pulse Stimulation\u2122 (NPS\u2122) technology, announced today the closing of its rights offering and the final results thereof.\n<\/p>\n

<\/a><\/p>\n

\nThe Company received basic subscriptions and over-subscriptions in excess of the $15 million limit in the rights offering. Available Units were allocated proportionately among those rights holders who exercised their over-subscription right based on the number of Units each rights holder subscribed for under its basic subscription rights, in accordance with the procedures described in the prospectus supplement relating to the rights offering. The remaining oversubscription amounts will be returned by Broadridge Corporate Issuer Solutions, Inc. (the \u201cSubscription Agent\u201d) to the investors.\n<\/p>\n

\nThe rights offering resulted in the sale of 7,317,072 units (the \u201cUnits\u201d), at a price of $2.05 per Unit, with each Unit consisting of one share of the Company\u2019s common stock, par value $0.001 per share, and one warrant to purchase one share of common stock. The common stock and warrants comprising the Units separated upon the closing of the rights offering and were issued individually. 7,317,072 shares of common stock and warrants to acquire up to an additional 7,317,072 shares of common stock were issued in the offering. The Company received aggregate gross proceeds from the rights offering of $15 million. If exercised, additional gross proceeds of up to $15 million may be received through the exercise of warrants issued in the rights offering. Each warrant is exercisable for one share of the Company\u2019s common stock at an exercise price equal to $2.05. Warrants are exercisable immediately and expire on the fifth anniversary of the closing of the rights offering.\n<\/p>\n

\nInvestors who participated in the rights offering should expect to see the shares and warrants issued to them in book-entry, or uncertificated, form. Shares, warrants and any excess subscription payments are expected to be distributed by the Subscription Agent on or about June 13, 2022.\n<\/p>\n

\nAfter giving effect to the issuance of 7,317,072 shares of common stock in the rights offering (but excluding up to 7,317,072 shares of common stock underlying the warrants issued in the rights offering), the Company has 37,119,352 shares of common stock issued and outstanding.\n<\/p>\n

\nThe rights offering was made pursuant to the Company\u2019s shelf registration statement on Form S-3, which became effective on August 21, 2020, the prospectus supplement dated May 4, 2022, and the prospectus supplement dated May 19, 2022, on file with the SEC containing the detailed terms of the rights offering. Subscription rights that were not exercised by 5:00 p.m., Eastern Time, on May 26, 2022, have expired.\n<\/p>\n

\nAbout Pulse Biosciences<\/b>\u00ae\n<\/p>\n

\nPulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company\u2019s proprietary Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX\u00ae System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of applications for which an optimal solution remains unfulfilled. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. Visit pulsebiosciences.com<\/a> to learn more.\n<\/p>\n

\nTo stay informed about the CellFX System, please visit CellFX.com<\/a> and sign-up for updates.\n<\/p>\n

\nPulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and\/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nAll statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse Biosciences\u2019 expectations concerning customer adoption and future use of the CellFX System to address a range of dermatologic conditions, statements relating to the effectiveness of the Company\u2019s NPS technology and the CellFX System to improve the quality of life for patients, and Pulse Biosciences\u2019 expectations, whether stated or implied, regarding its rights offering, financing plans and other future events. These statements are not historical facts but rather are based on Pulse Biosciences\u2019 current expectations, estimates, and projections regarding Pulse Biosciences\u2019 business, operations and other similar or related factors. Words such as \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201canticipate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences\u2019 control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences\u2019 filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:<\/b>
Pulse Biosciences
\n
Sandra Gardiner, EVP and CFO
\n
510.241.1077
\n
IR@pulsebiosciences.com<\/a>
or
\n
Gilmartin Group
\n
Philip Trip Taylor
\n
415.937.5406
\n
philip@gilmartinir.com<\/a><\/p>\n

Rights Offering Information, Subscription and Warrant Agent:<\/b>
Broadridge Corporate Issuer Solutions, Inc.
\n
Attn: BCIS Re-Organization Dept.
\n
P.O. Box 1317
\n
Brentwood, NY 11717-0718
\n
888.789.8409
\n
shareholder@broadridge.com<\/a><\/p>\n

Media:<\/b>
Tosk Communications
\n
Nadine D. Tosk
\n
504.453.8344
\n
nadinepr@gmail.com<\/a> or
\n
press@pulsebiosciences.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (the \u201cCompany\u201d or \u201cPulse Biosciences\u201d), a novel bioelectric medicine company commercializing the CellFX\u00ae System powered by Nano-Pulse Stimulation\u2122 (NPS\u2122) technology, announced today the closing of its rights offering and the final results thereof. The Company received basic subscriptions and over-subscriptions in excess of the $15 million limit in … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44926","6":"format-standard","7":"category-industry"},"yoast_head":"\nPulse Biosciences, Inc. Announces the Closing of Its Rights Offering - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (the \u201cCompany\u201d or \u201cPulse Biosciences\u201d), a novel bioelectric medicine company commercializing the CellFX\u00ae System powered by Nano-Pulse Stimulation\u2122 (NPS\u2122) technology, announced today the closing of its rights offering and the final results thereof. The Company received basic subscriptions and over-subscriptions in excess of the $15 million limit in ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-09T21:01:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220609006029\/en\/1279777\/21\/pulse-logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering\",\"datePublished\":\"2022-06-09T21:01:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\\\/\"},\"wordCount\":908,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220609006029\\\/en\\\/1279777\\\/21\\\/pulse-logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\\\/\",\"name\":\"Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220609006029\\\/en\\\/1279777\\\/21\\\/pulse-logo.jpg\",\"datePublished\":\"2022-06-09T21:01:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220609006029\\\/en\\\/1279777\\\/21\\\/pulse-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220609006029\\\/en\\\/1279777\\\/21\\\/pulse-logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/","og_locale":"en_US","og_type":"article","og_title":"Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering - Pharma Trend","og_description":"HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (the \u201cCompany\u201d or \u201cPulse Biosciences\u201d), a novel bioelectric medicine company commercializing the CellFX\u00ae System powered by Nano-Pulse Stimulation\u2122 (NPS\u2122) technology, announced today the closing of its rights offering and the final results thereof. The Company received basic subscriptions and over-subscriptions in excess of the $15 million limit in ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-09T21:01:55+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220609006029\/en\/1279777\/21\/pulse-logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering","datePublished":"2022-06-09T21:01:55+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/"},"wordCount":908,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220609006029\/en\/1279777\/21\/pulse-logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/","url":"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/","name":"Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220609006029\/en\/1279777\/21\/pulse-logo.jpg","datePublished":"2022-06-09T21:01:55+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220609006029\/en\/1279777\/21\/pulse-logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220609006029\/en\/1279777\/21\/pulse-logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/pulse-biosciences-inc-announces-the-closing-of-its-rights-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44926"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44926\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}